BR112015023256A2 - terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. - Google Patents

terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.

Info

Publication number
BR112015023256A2
BR112015023256A2 BR112015023256A BR112015023256A BR112015023256A2 BR 112015023256 A2 BR112015023256 A2 BR 112015023256A2 BR 112015023256 A BR112015023256 A BR 112015023256A BR 112015023256 A BR112015023256 A BR 112015023256A BR 112015023256 A2 BR112015023256 A2 BR 112015023256A2
Authority
BR
Brazil
Prior art keywords
benzyl
hexahydroimidazole
pyrido
pyrimidin
methyl
Prior art date
Application number
BR112015023256A
Other languages
English (en)
Inventor
Rao Nallaganchu Bhaskara
L Olson Gary
E Allen Joshua
Stogniew Martin
S Pottorf Richard
Original Assignee
Oncoceutics Inc
Provid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc, Provid Pharmaceuticals Inc filed Critical Oncoceutics Inc
Publication of BR112015023256A2 publication Critical patent/BR112015023256A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015023256A 2013-03-13 2014-03-13 terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. BR112015023256A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779828P 2013-03-13 2013-03-13
US201361904718P 2013-11-15 2013-11-15
PCT/US2014/025885 WO2014160130A1 (en) 2013-03-13 2014-03-13 Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one

Publications (1)

Publication Number Publication Date
BR112015023256A2 true BR112015023256A2 (pt) 2017-07-18

Family

ID=51527915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023256A BR112015023256A2 (pt) 2013-03-13 2014-03-13 terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.

Country Status (26)

Country Link
US (1) US9265765B2 (pt)
EP (2) EP2968294B1 (pt)
JP (3) JP6446025B2 (pt)
KR (2) KR102438135B1 (pt)
CN (1) CN105530937A (pt)
AU (3) AU2014244117B2 (pt)
BR (1) BR112015023256A2 (pt)
CA (2) CA3204801A1 (pt)
CY (1) CY1121735T1 (pt)
DK (1) DK2968294T3 (pt)
EA (1) EA037937B1 (pt)
ES (1) ES2734568T3 (pt)
HK (1) HK1217653A1 (pt)
HR (1) HRP20191181T1 (pt)
HU (1) HUE044238T2 (pt)
IL (2) IL241452B (pt)
LT (1) LT2968294T (pt)
ME (1) ME03470B (pt)
MX (2) MX2015012636A (pt)
NZ (2) NZ711948A (pt)
PL (1) PL2968294T3 (pt)
PT (1) PT2968294T (pt)
RS (1) RS59013B1 (pt)
SG (2) SG10201808496VA (pt)
SI (1) SI2968294T1 (pt)
WO (1) WO2014160130A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679934B1 (en) 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
SI2970473T1 (sl) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3662910A1 (en) * 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction
MD3250208T2 (ro) * 2015-01-30 2021-02-28 Oncoceutics Inc 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
EP3385395B9 (en) * 2015-08-17 2020-05-20 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
KR20170037260A (ko) 2015-09-25 2017-04-04 현대자동차주식회사 차량용 배터리 시스템 및 그 제어 방법
SG10202108306UA (en) 2016-01-29 2021-08-30 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
KR20170110520A (ko) * 2016-03-23 2017-10-11 고려대학교 산학협력단 mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
WO2017173496A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
AU2017310526B2 (en) * 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
WO2018085518A2 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2018129080A1 (en) * 2017-01-04 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Target genes in myc-driven neoplasia
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
IT201800004082A1 (it) * 2018-03-29 2019-09-29 Berlin Chemie Ag Composizioni farmaceutiche antitumorali per terapia combinata
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
EP4066837A4 (en) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN THE TREATMENT OF CANCER
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
EP2367425B1 (en) 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
EP3679934B1 (en) * 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
EP3662910A1 (en) 2014-03-31 2020-06-10 The Scripps Research Institute Pharmacophore for trail induction

Also Published As

Publication number Publication date
EP2968294B1 (en) 2019-05-01
JP2016512563A (ja) 2016-04-28
AU2014244117B2 (en) 2018-12-20
SG11201507247WA (en) 2015-10-29
CA3204801A1 (en) 2014-10-02
RS59013B1 (sr) 2019-08-30
EA037937B1 (ru) 2021-06-09
DK2968294T3 (da) 2019-07-15
AU2014244117A1 (en) 2015-10-08
EP2968294A4 (en) 2016-10-19
HK1217653A1 (zh) 2017-01-20
CA2905037C (en) 2023-08-29
AU2020233606A1 (en) 2020-10-01
PT2968294T (pt) 2019-07-19
NZ751509A (en) 2023-03-31
EP2968294A1 (en) 2016-01-20
JP2020172510A (ja) 2020-10-22
CY1121735T1 (el) 2020-07-31
KR20220123335A (ko) 2022-09-06
PL2968294T3 (pl) 2019-10-31
ES2734568T3 (es) 2019-12-10
HRP20191181T1 (hr) 2019-10-04
US9265765B2 (en) 2016-02-23
AU2019201896A1 (en) 2019-04-11
US20140271540A1 (en) 2014-09-18
KR20150136602A (ko) 2015-12-07
IL241452B (en) 2020-07-30
JP6446025B2 (ja) 2018-12-26
ME03470B (me) 2020-01-20
EA201591715A1 (ru) 2016-07-29
HUE044238T2 (hu) 2019-10-28
SI2968294T1 (sl) 2019-08-30
LT2968294T (lt) 2019-07-25
IL275623A (en) 2020-08-31
WO2014160130A1 (en) 2014-10-02
SG10201808496VA (en) 2018-10-30
EP3572083A1 (en) 2019-11-27
MX2019013643A (es) 2020-02-03
JP2018184411A (ja) 2018-11-22
CA2905037A1 (en) 2014-10-02
KR102438135B1 (ko) 2022-08-29
IL241452A0 (en) 2015-11-30
MX2015012636A (es) 2017-02-06
NZ711948A (en) 2020-02-28
CN105530937A (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
BR112015023256A2 (pt) terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.
HK1217697A1 (zh) 四氫咪唑並 氧氮雜卓衍生物
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
HK1219277A1 (zh) 新的三唑並 嘧啶衍生物
HK1246792A1 (zh) 6，7-二氫吡唑並[1，5-a]吡嗪-4(5h)-酮化合物
DK3318565T3 (da) Pyrrolo[2,3-D]pyrimidinyl-, pyrrolo[2,3-B]pyrazinyl- og pyrrolo[2,3-D]pyridinylacrylamider
BR112016011072A8 (pt) 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, sais destes e métodos de uso.
DK3177627T3 (da) Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ONCOCEUTICS, INC. (US) ; PROVID PHARMACEUTICALS INC. (US)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: ONCOCEUTICS, INC. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ONCOCEUTICS, INC. (US) ; PROVID PHARMACEUTICALS INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2649 DE 13/10/2021 POR TER SIDO INDEVIDA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ONCOCEUTICS, INC. (US) ; PROVID PHARMACEUTICALS INC. (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.7 NA RPI NO 2634 DE 29/06/2021 POR TER SIDO INDEVIDA.

B25G Requested change of headquarter approved

Owner name: ONCOCEUTICS, INC. (US) ; PROVID PHARMACEUTICALS INC. (US)

B25A Requested transfer of rights approved

Owner name: ONCOCEUTICS, INC. (US)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]